Precision Medicine in Oncology®

Dr. Axel Hoos from Bristol Myers-Squibb on Tools Available to Measure Ipilimumab's Success

Dr. Lynn M. Schuchter from Penn Med on the Next Steps in Melanoma Research

Dr. Mark G. Kris from memorial sloan-kettering Talks About the importance of Defining the broad term Biomarkers

Dr. Axel Hoos the medical lead in Immunology/Oncology at Bristol-Myers Squibb Discusses the Clinical Kinetics of Immunotherapy

Researchers have reported that acute myocardial infarction (MI) patients who are exposed to low-dose ionizing radiation from imaging and therapeutic procedures may be at increased risk of cancer.

Nurse scientist Donna Berry, PhD, RN, received the 2011 ONS Distinguished Researcher Award, which recognizes a nurse researcher whose work has enhanced the science and practice of oncology nursing.

Population stratification refers to differences in allele frequencies between cases and controls, resulting from systematic differences in ancestry, as opposed to associations between genes and disease.

Martine Piccart-Gebhart, MD, PhD is a professor of oncology at the Universite Libre de Bruxelles and director of the Medicine department at the Jules Bordet Institute in Brussels, Belgium.

Dr. Brian Rini from the Cleveland Clinic Taussig Cancer Institute on the Results From His Axitinib and Sorafenib Trial

The first drug that successfully targeted the HER2 pathway in cancer treatment generated much excitement.

Dr. Jeffrey Infante from Sarah Cannon Research Institute on the Next Step in Melanoma Research

Dr. Mark Kris from Memorial Sloan-Kettering Cancer Center Discusses the Pemetrexed Clincal Trial Results

Vismodegib has demonstrated positive overall response rates in patients with advanced basal cell carcinoma.

Patients with basal cell carcinoma had an eightfold decrease in lesion area when treated with GDC-0449

During the past 20 years, disease management systems have mushroomed in medicine

Both industry and clinical sources agree that cancer vaccine research is finally on the right track to achieve major advances in treatment.

The investigators developed a computer tool that is dramatically better for finding genetic missteps that promote cancer.

Dr Paz-Ares from Seville University Hospital Discusses Pemetrexed Clinical Trial

Currently, more than 250 physicians and scientists work in concert to provide state-of- the art diagnosis, treatment, and aftercare for the more than 20,000 patients seen each year at the UW hospitals, clinics, and affiliate clinical facilities

Dr. Chapman From Memorial Sloan-Kettering Describes the Vemurafenib Clinical Trial

Dr. Vogelzang from the Comprehensive Cancer Centers of Nevada Discusses Cabozantinib Trial Design

Dr. Cella from Northwestern University Feinberg School of Medicine on Patient Assessment Reference Scores

Matching patients with targeted therapies based on molecular profile results in superior clinical outcomes

As a child Joyce Ann O'Shaughnessy enjoyed science and her home chemistry set. Still, she didn't give much thought to pursuing the subject beyond the confines of her school - until she faced a tragedy.

An experimental melanoma vaccine gp100 peptide vaccine in combination with IL2 may shrink tumors and prevent the progression of late-stage melanoma